Kumar Pvsn Kiran, Banerjee Mithu, Bajpayee Archana, Mandal Saptarishi, Mitra Prasenjit, Sharma Praveen, Misra Sanjeev, Bhardwaj Pankaj
Department of Biochemistry, All India Institute of Medical Sciences, Basni Phase -2 Jodhpur, Rajasthan India.
Deparment of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur, India.
Indian J Clin Biochem. 2022 Oct;37(4):423-431. doi: 10.1007/s12291-021-01012-w. Epub 2021 Nov 18.
SARS-CoV-2, a novel coronavirus, emerged a year ago in Wuhan, China causing a new pandemic. Convalescent plasma therapy has been applied previously to many infectious diseases and has shown a successful result. This study was planned to assess the Anti-SARS-CoV-2 IgG antibody levels in convalescent COVID-19 patients. In this study, serum samples from 210 persons infected by SARS-CoV-2, treated and discharged from the hospital were collected. Anti-SARS-CoV-2 IgG antibody levels were detected using a chemiluminescence assay. A directory of convalescent plasma donors was created. Anti-SARS-CoV-2 IgG antibody levels vary substantially in the study population with a mean of 51.2 AU/ml. On comparing the serum anti-SARS-CoV-2 IgG antibody levels, a significant difference was observed between the subjects who had cough and those who did not (p = 0.0004). Similar significant findings were found with total protein and globulin levels on comparing the individuals with different antibody status (positive, negative and equivocal). The middle-aged and old age people had high Ab titres compared to younger individuals and the duration of the hospital stay was found to be positively correlated with the anti-SARS-CoV-2 IgG antibody. Cough, age and duration of the hospital stay was found to play a significant role in the development of Anti-SARS-CoV-2 IgG levels. Further, the data suggests that blood groups have a lesser impact on the severity of disease and the development of antibodies. Patients who present with the cough are more likely to develop antibodies.
新型冠状病毒SARS-CoV-2于一年前在中国武汉出现，引发了一场新的大流行。恢复期血浆疗法此前已应用于多种传染病，并取得了成功。本研究旨在评估COVID-19康复患者体内抗SARS-CoV-2 IgG抗体水平。在本研究中，收集了210名感染SARS-CoV-2并经治疗出院的患者的血清样本。采用化学发光法检测抗SARS-CoV-2 IgG抗体水平。建立了恢复期血浆供者名录。研究人群中抗SARS-CoV-2 IgG抗体水平差异很大，平均为51.2 AU/ml。比较血清抗SARS-CoV-2 IgG抗体水平时，咳嗽患者与未咳嗽患者之间存在显著差异（p = 0.0004）。比较不同抗体状态（阳性、阴性和可疑）的个体时，总蛋白和球蛋白水平也有类似的显著发现。与年轻人相比，中年人和老年人的抗体滴度较高，且住院时间与抗SARS-CoV-2 IgG抗体呈正相关。发现咳嗽、年龄和住院时间对抗SARS-CoV-2 IgG水平的产生有显著影响。此外，数据表明血型对疾病严重程度和抗体产生的影响较小。出现咳嗽的患者更有可能产生抗体。
